These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16737094)

  • 21. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activity of clinical laboratory physicians in national health insurance].
    Mori M
    Rinsho Byori; 2005 Nov; 53(11):1030-5. PubMed ID: 16372754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The transparency commission: evaluation and re-evaluation].
    Bergmann JF
    Presse Med; 2001 May 26-Jun 2; 30(19):941-6. PubMed ID: 11433724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Generic drugs in the medical-economic context of drug prescriptions].
    Bouvenot G; Villani P; Bouvenot J
    Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France.
    Le Pen C; Priol G; Lilliu H
    Eur J Health Econ; 2003; 4(1):30-6. PubMed ID: 15609166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telemedicine: what framework, what levels of proof, implementation rules.
    Zannad F; Maugendre P; Audry A; ; Avril C; Blaise L; Blin O; Burnel P; Falise-Mirat B; Girault D; Giri I; Goehrs JM; Lassale C; Le Meur R; Leurent P; Ratignier-Carbonneil C; Rossignol P; Satonnet E; Simon P; Treluyer L
    Therapie; 2014; 69(4):339-54. PubMed ID: 25230356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunization: process of elaborating guidelines and their evolution in France].
    Floret D
    Ann Pharm Fr; 2009 May; 67(3):219-23. PubMed ID: 19446673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
    Yang BM; Bae EY; Kim J
    Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: Cost-effectiveness analysis from the perspective of the French national health insurance system.
    Pistone T; Schwarzinger M; Chauvin P; Ezzedine K; Receveur MC; Djossou F; Siriwardana M; Larouzé B; Malvy D
    Health Policy; 2008 Dec; 88(2-3):186-99. PubMed ID: 18440663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of post-registration studies for reimbursement renewal.
    Molimard M; Bamberger M; Vray M
    Therapie; 2009; 64(3):203-13. PubMed ID: 19671433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmaceuticals: a strategic national industry].
    Hollender L
    Bull Acad Natl Med; 2004; 188(4):701-13. PubMed ID: 15587688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
    Cleemput I; Franken M; Koopmanschap M; le Polain M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):358-66. PubMed ID: 22980497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New strategies for medical data mining, part 1: dynamic and performance-based reimbursement.
    Reiner B
    J Am Coll Radiol; 2010 Dec; 7(12):975-9. PubMed ID: 21129690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alzheimer's disease and pharmacists in contact with the public].
    Dreux C
    Ann Pharm Fr; 2009 Mar; 67(2):104-15. PubMed ID: 19298894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of drugs in therapeutic strategies].
    Castaigne A
    Rev Prat; 2002 Mar; 52(5):491-6. PubMed ID: 11949500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proposal of a French health identification number interoperable at the European level.
    Quantin C; Allaert FA; Avillach P; Riandey B; Fieschi M; Fassa M; Cohen O
    Stud Health Technol Inform; 2007; 129(Pt 1):503-7. PubMed ID: 17911768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.